Last reviewed · How we verify
Triphosphoric Acid Adenosine Ester (ADENOSINE TRIPHOSPHATE)
ADENOSINE TRIPHOSPHATE is a marketed drug used for the treatment of supraventricular arrhythmia, with a key composition patent expiring in 2028. Its mechanism of action, involving the binding to adenosine receptors to slow down abnormal heart rhythms, provides a targeted approach to managing arrhythmias. The primary risk is the upcoming patent expiry, which could lead to increased competition from generic versions.
At a glance
| Generic name | ADENOSINE TRIPHOSPHATE |
|---|---|
| Drug class | Vitamin C [EPC] |
| Target | P2X purinoceptor 3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Supraventricular arrhythmia
Common side effects
Key clinical trials
- Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study (PHASE2)
- Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy (PHASE4)
- Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy (NA)
- Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) (PHASE2)
- Clinical Trial of TQB3002 in Patients With Advanced Cancers (PHASE1)
- The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges (PHASE1)
- Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triphosphoric Acid Adenosine Ester CI brief — competitive landscape report
- Triphosphoric Acid Adenosine Ester updates RSS · CI watch RSS